Search results
Added:
5 months ago
AHA 2023 — Investigator, Dr George Bakris (UChicago Medicine, US) is interviewed by Dr Sukriti Banthiya, CardioNerds Ambassador on the new findings of KARDIA-1 trial (NCT04936035).This randomized, double-blind, placebo-controlled, dose-ranging multicenter study (Alnylam Pharmaceuticals) aimed to evaluate the effect of ALN-AGT01 (zilbesiran) on systolic and diastolic blood pressure in patients…
View more
Added:
10 months ago
ESC-HFA 23 – Prof Paul Kalra (Portsmouth Hospitals NHS Trust, UK) joins us onsite to discuss the IRONMAN trial (NCT02642562).
The IRONMAN trial aimed to study the effectiveness of intravenous iron in patients with heart failure and iron deficiency when compared to standard care. It showed that administration of IV FDI led to lower rates of recurrent heart failure hospitalisations and…
View more
Added:
3 years ago
The yearly incidence of stroke in patients with atrial fibrillation (AF) is approximately 5%, which is five times higher than in comparable populations in sinus rhythm (SR). The stroke risk largely depends on the underlying heart disease. In 'lone' AF (absence of heart disease) the stroke risk is only 0.5% per year, whereas in AF associated with rheumatic valvular heart disease (VHD), like mitral…
View more
Added:
3 years ago
The yearly incidence of stroke in patients with atrial fibrillation (AF) is approximately 5%,1 which is five times higher than in comparable populations in sinus rhythm (SR). The stroke risk largely depends on the underlying heart disease. In 'lone' AF (absence of heart disease) the stroke risk is only 0.5% per year,2 whereas in AF associated with rheumatic valvular heart disease (VHD), like…
View more
Added:
3 years ago
The field of pulmonary arterial hypertension (PAH) has recently been characterised by rapid improvements in therapeutic options and corresponding improvements in patient outcomes. In 1991, estimates from the US Department of Health and Human Services National Institutes of Health (NIH) Registry painted a grim portrait of survival in patients with pulmonary hypertension – then called primary…
View more
Added:
11 months ago
ESC-HFA 23 — We are joined by Prof Marianna Fontana (University College London, UK), as she outlines the key findings from the phase 3 APOLLO-B study (Alnylam Pharmaceuticals) (NCT03997383).
APOLLO-B investigated the use of patisiran, a transthyretin-directed small interfering RNA, in a cohort of patients with cardiac amyloidosis. 360 patients were enrolled in the trial and were randomized 1:1…
View more
Added:
2 years ago
In this short interview from our coverage of ACC.22 late-breaking trials, Dr Manesh Patel (Duke Heart Center, US) discusses the multicentre, randomised, double-blind PACIFIC-AF trial (Bayer)(NCT04218266).
The trial sought to determine the efficacy of the oral FXIa inhibitor asundexian and evaluate the safety of the drug, compared to the non-vitamin K oral anticoagulant (NOAC) apixaban, in…
View more
Added:
3 years ago
In developed countries, the number of atrial fibrillation (AF) catheter ablation procedures increases every year. Continuous scientific and technological innovation in the area of AF ablation has broadened the spectrum of therapeutic options for patients with AF, and it is likely to be a contributing factor in making AF ablation a practice no longer restricted to a few operators with greater…
View more
Added:
3 years ago
Congenital heart diseases (CHDs) are among the most common congenital malformations at birth, with an incidence of 8/1,000 live births. These defects are characterised by a heterogeneous group of abnormal communications and connections between the cardiac chambers and vessels with different haemodynamic consequences and, hence, varying need for follow-up and interventions. The most common forms…
View more
Added:
1 year ago
EASD 22 - Dr Steven Nissen (Cleveland Clinic, US) joins us to discuss the findings of the SURMOUNT-MMO trial. This study aimed to evaluate the effect of tirzepatide in type II diabetes patients who have obesity, or are overweight.
Questions:
1. What was the rationale behind this study?
2. What is the mechanism of action of Tirzepatide?
3. What was the study design?
4. What were the main outcomes…
View more
